Melanoma CT

	Melanoma Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Melanoma from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
Diagnostic Study of Choice
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X-ray
Echocardiography and Ultrasound
CT scan
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Melanoma CT On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Melanoma CT All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Melanoma CT
CDC on Melanoma CT
Melanoma CT in the news
Blogs on Melanoma CT
Directions to Hospitals Treating Melanoma
Risk calculators and risk factors for Melanoma CT

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Yazan Daaboul, M.D.; Serge Korjian M.D.

Overview

Melanoma can appear as a soft tissue mass on CT scan. Chest CT scan is recommended for the diagnosis of metastatic lesions in patients who have been diagnosed with stage IA-IV melanoma and for secondary prevention of melanoma in patients who were previously diagnosed with Stage IIB-IV melanoma (annually for 5 years).

Melanoma can appear as a soft tissue mass on CT scan.^[1]
Chest CT scan of patients with pulmonary metastatic lesions can demonstrate enlarged mediastinal adenopathy.^[2]
CT scan along with other modalities can also be useful for the staging of the disease, therapy assessment, and prognosis determination.^[3]
Chest CT scan is the preferred choice of chest imaging modality and is recommended for the diagnosis of metastatic lesions in the following conditions:^[4]

In patients with stage IA-IV melanoma^[4]
For secondary prevention of melanoma in patients who were previously diagnosed with stage IIB-IV melanoma (annually for 5 years)^[4]

↑ Brant JM (November 2013). "Breathlessness with pulmonary metastases: a multimodal approach". J Adv Pract Oncol. 4 (6): 415–22. PMID 25032021.
↑ Powell CA (March 2017). "Pulmonary Infiltrates in a Patient With Advanced Melanoma". J. Clin. Oncol. 35 (7): 705–708. doi:10.1200/JCO.2016.69.9793. PMID 28029320.
↑ Perng P, Marcus C, Subramaniam RM (August 2015). "(18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis". AJR Am J Roentgenol. 205 (2): 259–70. doi:10.2214/AJR.14.13575. PMID 26204273.
↑ ^4.0 ^4.1 ^4.2 Coit DG, Andtbacka R, Anker CJ, Bichakjian CK, Carson WE, Daud A; et al. (2013). "Melanoma, version 2.2013: featured updates to the NCCN guidelines". J Natl Compr Canc Netw. 11 (4): 395–407. PMID 23584343.